Similar effects have been observed in other cancers such as pancreatic cancer, where combined ETC-159 (PORCN inhibitor) and pictilisib treatment synergistically reduced pancreatic cancer cell proliferation and xenograft tumor growth [112]. Here, PORCN is linked to familial pancreatic carcinoma.